Immuron (NASDAQ:IMRN – Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 30th, there was short interest totaling 26,156 shares, a decrease of 60.6% from the October 15th total of 66,371 shares. Based on an average daily trading volume, of 15,900 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.3% of the company’s stock are sold short.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Immuron in a research note on Monday, September 21st. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company presently has a consensus rating of “Sell”.
View Our Latest Analysis on IMRN
Immuron Trading Up 2.8%
Shares of NASDAQ IMRN traded up $0.02 during trading hours on Monday, hitting $0.90. The stock had a trading volume of 23,750 shares, compared to its average volume of 17,799. The firm’s 50-day moving average price is $1.09 and its two-hundred day moving average price is $1.01. Immuron has a 52 week low of $0.68 and a 52 week high of $1.99.
Immuron (NASDAQ:IMRN – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.08) earnings per share for the quarter. The company had revenue of $1.27 million for the quarter.
About Immuron
Immuron Limited is an Australian biopharmaceutical company that develops and commercializes oral antibody-based products. Its approach uses targeted antibodies intended to bind pathogens or other biological targets in the gastrointestinal tract. The company’s principal commercial product is Travelan, an oral product designed to help prevent travelers’ diarrhea. Immuron also develops investigational therapies for infectious and inflammatory conditions, including candidates focused on Clostridioides difficile infection and other gastrointestinal diseases.
Further Reading
- Five stocks we like better than Immuron
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Immuron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron and related companies with MarketBeat.com's FREE daily email newsletter.
